Imagine a plaster that can detect eczema and release healing compounds on its own, or a brick that uses genetically modified bacteria to repair its own cracks. These are examples of engineered living materials (ELMs) — a class of products that incorporate living microorganisms such as bacteria, yeast or fungi to perform specific functions. The potential applications span construction, medicine and environmental technology.
But according to a new report from Wageningen University & Research (WUR), European companies hoping to bring these products to market face a thicket of regulatory uncertainty that could stifle innovation and drive investment elsewhere.
Justus Wesseler, chair of the Agricultural Economics and Rural Policy Group at WUR and co-author of the report, told WUR that firms often cannot determine in advance which EU regulations apply to their products or what approval procedures are required. This uncertainty, he said, creates a disincentive for research and development.
"Companies need to invest in research and development, even though it is not always clear in advance which approval procedures they will have to go through or how much time and money these will require," Wesseler said. "The longer this uncertainty persists, the more likely companies are to postpone investment or decide to develop their products elsewhere. We need to be careful not to lose our leading position in this field of innovation."
The report, titled The Law and Economics of Regulation of Engineered Living Materials in the EU, was co-authored by Wesseler and Kai Purnhagen. It examines the European regulatory framework for ELMs and identifies several legal grey areas.
One key question, according to the report, is how to determine whether a living material is sufficiently "contained" to prevent genetically modified microorganisms from escaping into the environment. Wesseler illustrated the problem with the example of a brick containing genetically modified bacteria that can repair cracks. To qualify as "contained use" under EU regulations, manufacturers must demonstrate that the microorganisms remain inside the material. But, Wesseler asked, "How can you demonstrate this for a material that may become damaged during use? And which regulations apply if the bacteria can escape after all?"
The report also highlights specific research projects that raise complex regulatory questions. One is the European project NextSkins, which is developing a living plaster that mimics functions of human skin. The plaster consists of a structure made from bacterial cellulose, produced by bacteria, that contains living yeast cells. Researchers have genetically modified these yeast cells to produce substances that can help treat eczema. The product raises a fundamental question: should it be regulated as a medicinal product, a medical device, or a genetically modified organism?
Another project, Fungateria, combines fungal networks (mycelium) with genetically modified bacteria containing genetic circuits that enable specific functions. Potential applications include biodegradable disposable slippers for the hospitality industry and insulation panels that can capture CO₂. The report asks how existing GMO regulations should apply to such composite materials, especially when the material eventually breaks down and the modified bacteria may enter the environment.
Wesseler also pointed to uncertainty over liability. If a living material containing genetically modified bacteria is used to produce nutrients but later turns out to also produce a harmful substance, who is responsible? "The producer of the living material, the manufacturer that incorporated it into a food product, or the company selling the final product?" he asked.
The report argues that European regulations should be better aligned with the specific characteristics of ELMs. Instead of focusing primarily on the technology used to genetically modify an organism, the researchers say, regulatory assessments should also consider the properties, applications and potential risks of the final product. They call for clearer approval procedures and better cooperation between regulatory authorities such as the European Food Safety Authority (EFSA) and the European Medicines Agency (EMA).
One concrete suggestion from the report is the creation of a European body that could help companies prepare their applications for regulatory approval. "This would give companies a clearer understanding of what to expect and which regulations apply to their products," Wesseler said. "At the same time, it could help bring new products to market more quickly."
For students and researchers in biotechnology, materials science and related fields, the report underscores that regulatory literacy may be as important as technical innovation when it comes to bringing new products to market in Europe. The findings also suggest that the continent's leadership in this emerging field is not guaranteed — and that policy reform may be needed to keep pace with scientific advances.